The European Psychiatry Association (EPA) - Early Career Psychiatrists Committee (ECPC) Survey on trainees’ attitudes for Therapeutic Drug Monitoring (TDM) use and utility for antipsychotic treatment
Caution: JavaScript execution is disabled in your browser or for this website. You may not be able to answer all questions in this survey. Please, verify your browser parameters.

The European Psychiatry Association (EPA) - Early Career Psychiatrists Committee (ECPC) Survey on trainees’ attitudes for Therapeutic Drug Monitoring (TDM) use and utility for antipsychotic treatment

The European Psychiatry Association (EPA) - Early Career Psychiatrists Committee (ECPC) is requesting your assistance with completing a survey. The goal of this project is to survey trainees and young psychiatrists to understand attitudes regarding the use and utility of therapeutic drug monitoring (TDM), i.e. the measurement of blood levels of antipsychotics, as part of treatment with antipsychotics including clozapine. In order to do so, we have drafted a short survey consisting of 12 questions to gather data on TDM attitudes, practices, and clinical setting.

By completing the survey, I confirm that: I am 18 years old or older, I am an adult psychiatry trainee or an early career adult psychiatrist and I agree to participate in this study. I am aware the survey can only be completed once.

Thank you for your time, consideration, and assistance!

There are 12 questions in this survey.
This survey is anonymous.

The record of your survey responses does not contain any identifying information about you, unless a specific survey question explicitly asked for it.

If you used an identifying access code to access this survey, please rest assured that this code will not be stored together with your responses. It is managed in a separate database and will only be updated to indicate whether you did (or did not) complete this survey. There is no way of matching identification access codes with survey responses.

Demographics
Gender
(This question is mandatory)
Have you completed residency?
(This question is mandatory)
Years within residency
(This question is mandatory)
Years after residency
(This question is mandatory)
Main clinical setting
(This question is mandatory)
Number of antipsychotic-medicated patients treated/month
(This question is mandatory)
How often do you use TDM for any antipsychotic other than clozapine (if available)
(This question is mandatory)
In which country do you practice?
TDM Survey
Please indicate to what degree you agree with the following statements.
(This question is mandatory)

Perceived potential benefits and negative aspects of therapeutic drug monitoring

Therapeutic drug monitoring directly enables individualized prescribing of mood stabilizers
Therapeutic drug monitoring for antipsychotics is a bad idea
Therapeutic drug monitoring for antipsychotics does not help the clinician to minimize the risk of toxicity
Therapeutic drug monitoring for antipsychotics directly enables individualized prescribing of antipsychotics
Therapeutic drug monitoring for antipsychotics helps the clinician to avoid subtherapeutic dosing
Antipsychotic plasma concentration levels are not relevant for drug action in the brain
Therapeutic drug monitoring for antipsychotics can assist in minimizing the risk of dose-related side effects
Therapeutic drug monitoring for long-acting injectable antipsychotics can be beneficial
The scientific evidence for therapeutic drug monitoring for risperidone is weak
The scientific evidence for therapeutic drug monitoring for clozapine is strong
The scientific evidence for therapeutic drug monitoring for olanzapine is weak
(This question is mandatory)

Perception of likely attitudes of patients

Patients will only want to know the therapeutic drug monitoring result if it suggests dose reduction and not increase
Obtaining a blood sample from a psychotic patient is as easy as with any other patient
Therapeutic drug monitoring should only be optional and not compulsory for patients
Patients with psychosis will never agree to therapeutic drug monitoring for antipsychotics
Patients will readily request therapeutic drug monitoring for antipsychotics
Patients will complain of being tested like “guinea pigs” or “rats” if I suggest therapeutic drug monitoring
(This question is mandatory)

Impact of routine therapeutic drug monitoring on changing clinical practice

I routinely use therapeutic drug monitoring for clozapine
I have never used therapeutic drug monitoring for antipsychotics other than clozapine
If therapeutic drug monitoring for antipsychotics was readily available, I would use it
Therapeutic drug monitoring for antipsychotics will have no impact on dose-related decision making
Therapeutic drug monitoring for antipsychotics is only a very small contributory factor to guiding dose choice
Therapeutic drug monitoring for antipsychotics will reduce arguments about dose between doctors and patients
Therapeutic drug monitoring for antipsychotics will cost your healthcare system more money than it might save by its use
Therapeutic drug monitoring for antipsychotics will reduce likelihood of clinical relapse
Therapeutic drug monitoring for antipsychotics will increase length of stay for acutely psychotic inpatients
Therapeutic drug monitoring for antipsychotics will improve clinical outcomes
(This question is mandatory)
Potential barriers to therapeutic drug monitoring
Doctors will primarily use therapeutic drug monitoring results for antipsychotics to guide dose
Doctors will only use therapeutic drug monitoring results for antipsychotics to check for medication adherence
Patients will request therapeutic drug monitoring testing to prove they have been taking their medication
I do not have time to wait for an antipsychotic therapeutic drug monitoring result before changing dose
Doctors will ignore the results of therapeutic drug monitoring for antipsychotics when considering dose
There is a laboratory to which I can readily send samples for antipsychotic therapeutic drug monitoring testing
It is impossible to take a morning therapeutic drug monitoring blood sample before the morning dose is taken
The therapeutic drug monitoring laboratory should take no longer than 4 days to provide a sample test result
Therapeutic drug monitoring for antipsychotics requires too many blood tests for every dose change
The interpretation of the therapeutic drug monitoring results for antipsychotics is straightforward
 
Close